Compare Target Corporation (TGT) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Target Corporation vs 10X Genomics Inc — how do they compare? Target Corporation trades at $153.94 (market cap $69.17B), while 10X Genomics Inc trades at $57.7 (market cap $7.61B). The key difference: Target Corporation is far larger — about 9.1× 10X Genomics Inc's market cap, and Target Corporation pays a 3.05% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TGT | TXG | |
|---|---|---|
Market Cap | $69.17B | $7.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $152.35 | $58.57 |
52-Week Low | $83.68 | $11.34 |
Enterprise Value | $84.47B | $7.14B |
Dividend Yield | 3.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Target Corporation (TGT) trades at $153.50, up 0.93% today, with strong technical momentum and bullish moving averages. Recent earnings beats and the appointment of a Chief AI Officer highlight operational strength. The stock is near its 52-week high, supported by positive analyst sentiment and consistent dividend payments.
Outlook remains positive with solid fundamentals and growth initiatives, though overbought technical indicators and competitive retail pressures pose risks. Revenue stability and margin improvements are key drivers, but investor caution is warranted near resistance levels.
TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.
Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
